Related Experiment Videos
Controlled epidemiological study of live measles vaccines in Poland
Insights
This study compared two live measles vaccines, Schwarz and L-16, in 851 children. Both vaccines showed similar safety and efficacy, with Schwarz demonstrating a slightly higher serological conversion rate.
Area of Science:
- Immunology
- Vaccinology
- Pediatrics
Background:
- Measles remains a significant public health concern globally.
- Effective vaccination is crucial for measles prevention.
- Evaluating different live measles vaccine strains is essential for optimizing immunization strategies.
Purpose of the Study:
- To compare the safety, immunogenicity, and efficacy of two live measles vaccines: Schwarz and L-16.
- To assess clinical reactions, antibody responses, and seroconversion rates.
- To evaluate long-term protection against measles over a 24-month period.
Main Methods:
- A controlled clinical trial involving 851 children, including a unvaccinated control group.
- Monitoring of clinical symptoms for vaccine reactions between days 5 and 15 post-vaccination.
- Measurement of geometric mean antibody titers and serological conversion percentages.
- Epidemiological follow-up for 24 months to assess protection against measles.
Main Results:
- Both Schwarz and L-16 vaccines exhibited similar safety profiles with no significant clinical objections.
- Geometric mean antibody titers were not significantly different between the two vaccines (Schwarz: 1:132, L-16: 1:100).
- The Schwarz vaccine demonstrated a significantly higher serological conversion rate (97%) compared to the L-16 vaccine (82.9%).
- Both vaccines provided comparable protection, with over 91% of children protected against measles during the 24-month observation period, indicating similar immunogenic properties, with Schwarz being slightly superior.
Conclusions:
- The Schwarz and L-16 live measles vaccines are safe and effective for use in children.
- The Schwarz vaccine shows a higher serological conversion rate, suggesting potentially stronger immunogenicity.
- Both vaccines offer substantial and comparable long-term protection against measles.
- Further research may explore the long-term implications of the observed differences in seroconversion rates.
Abstract:
Two types of live measles vaccine, the Schwarz and the L-16 vaccines, were tested in a controlled study. The control group consisted of children who were not vaccinated. Altogether 851 children were included in the trial.Observations of clinical symptoms between the 5th and 15th days after vaccination showed that both vaccines were similar with regard to reactions, and no clinical evidence of objections to their use was discovered.The geometric mean antibody titres after vaccination with the Schwarz and L-16 vaccines were not significantly different (1: 132 and 1: 100, respectively). Significant differences were found when the percentages of serological conversions were compared-Schwarz, 97%; L-16, 82.9%.The epidemiological observations were carried out for 24 months from the date of vaccination and showed that the immunogenic properties of both vaccines are similar, the Schwarz vaccine being slightly better. Both vaccines protected more than 91% of children against measles for the period of observation.